U.S. markets closed
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • Dow 30

    34,382.13
    +360.68 (+1.06%)
     
  • Nasdaq

    13,429.98
    +304.99 (+2.32%)
     
  • Russell 2000

    2,224.63
    +53.68 (+2.47%)
     
  • Crude Oil

    65.51
    +1.69 (+2.65%)
     
  • Gold

    1,844.00
    +20.00 (+1.10%)
     
  • Silver

    27.52
    +0.47 (+1.72%)
     
  • EUR/USD

    1.2146
    +0.0062 (+0.51%)
     
  • 10-Yr Bond

    1.6350
    -0.0330 (-1.98%)
     
  • GBP/USD

    1.4102
    +0.0050 (+0.36%)
     
  • USD/JPY

    109.3470
    -0.0870 (-0.08%)
     
  • BTC-USD

    48,948.00
    +88.78 (+0.18%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

Danaher (DHR) Surges 3.4%: Is This an Indication of Further Gains?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Danaher Corporation DHR shares ended the last trading session 3.4% higher at $242.84. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8.2% gain over the past four weeks.

Danaher’s rally is largely driven by optimism over the company’s financial update on first-quarter 2021 performance. The company currently expects its core revenues to grow more than its previously guided range in the first quarter. For the quarter, Danaher anticipates core revenues, including Cytiva, to rise about 29% compared with growth of mid-to high-teens range guided previously.

Price and Consensus

Price Consensus Chart for DHR
Price Consensus Chart for DHR

This industrial and medical device maker is expected to post quarterly earnings of $1.67 per share in its upcoming report, which represents a year-over-year change of +59.1%. Revenues are expected to be $6.08 billion, up 39.9% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Danaher, the consensus EPS estimate for the quarter has been revised 0.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on DHR going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research